author-photo

Roy Vitkon

Tel Aviv Sourasky Medical Center

3

Papers

7

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.

2021 Therapeutic advances in hematology
Show All
- Source
- Cite
- Save
Citations (0)
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.

2020 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (6)
Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)